Opthea Ltd
Biopharma that discontinued its wet AMD therapy after its lead drug failed Phase 3 trials.
OPT | NDAQ
Overview
Corporate Details
- ISIN(s):
- US68386J2087
- LEI:
- Country:
- United States of America
- Address:
- LEVEL 4, 3141 SOUTH YARRA
- Website:
- https://opthea.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Opthea Ltd. is a clinical-stage biopharmaceutical company that was focused on developing novel therapies for vision-threatening retinal diseases. The company's primary development program centered on its lead candidate, sozinibercept (OPT-302), a first-in-class biologic inhibitor of VEGF-C and VEGF-D. Sozinibercept was being evaluated in combination with standard-of-care anti-VEGF-A therapies for the treatment of wet age-related macular degeneration (wet AMD), with the goal of delivering superior visual outcomes. However, in March 2025, the company announced that its pivotal Phase 3 clinical trials (COAST and ShORe) did not meet their primary endpoints, leading to the discontinuation of the development program and significant corporate restructuring.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Opthea Ltd filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Opthea Ltd
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Opthea Ltd via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
